September 28, 2017

FDA alerts healthcare providers about EVAR graft endoleaks

By: Judy Mathias
Share

Editor's Note

The Food & Drug Administration (FDA) on September 28 sent letters to vascular and cardiothoracic surgeons, radiologists, and cardiologists, alerting them to an increase in Type III endoleaks associated with endovascular graft systems used in endovascular aneurysm repair (EVAR) for abdominal aortic and aorto-iliac aneurysms.

The FDA’s letter encourages healthcare providers to report Type IIIa and IIIb endoleak events to the manufacturer and FDA.

Read More >>

Join our community

Learn More
Video Spotlight
Live chat by BoldChat